Tag Archives: VRTU

Top 5 Medical Stocks To Own Right Now

Image source: The Motley Fool.

Warrior Met Coal, Inc.  (NYSE:HCC)Q4 2018 Earnings Conference CallFeb. 21, 2019, 4:30 p.m. ET

Contents:
Prepared Remarks Questions and Answers Call Participants
Prepared Remarks:

Operator

Good afternoon. My name is Jamie, and I will be your conference operator today. At this time I would like to welcome everyone to the Warrior Met Coal Fourth Quarter and Full Year 2018 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speaker’s remarks, there will be a question-and-answer session. (Operator Instructions) Thank you.

Before we begin, I have been asked to note that today’s discussion may contain forward-looking statements and actual results may differ materially from those discussed. For more information regarding forward-looking statements, please refer to the company’s press release and SEC filings. I have also been asked to note that the company has posted reconciliations of the non-GAAP financial measures discussed during this call in the tables accompanying the company’s earnings press release located on the Investors section of the company’s website at www.warriormetcoal.com. In addition to the earnings release, the company has posted a brief supplemental slide presentation to the Investors section of its website at www.warriormetcoal.com.

Top 5 Medical Stocks To Own Right Now: Cytokinetics, Incorporated(CYTK)

Cytokinetics, Incorporated, incorporated on August 5, 1997, is a biopharmaceutical company. The Company is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company’s drug candidates include tirasemtiv, CK-2127107 and omecamtiv mecarbil.

Tirasemtiv

The Company’s lead drug candidate from its skeletal muscle contractility program, tirasemtiv, is a skeletal muscle troponin activator. The Company holds the rights to tirasemtiv and is independently developing this drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). It has conducted a Phase II clinical trials program for tirasemtiv, including a Phase IIb clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). Its skeletal muscle contractility program is focused on the activation of the skeletal sarcomere, the basic unit of skeletal muscle contraction.

CK-2127107

The Company is developing CK-2127107, a skeletal muscle troponin activator. The Company has conducted approximately five Phase I clinical trials of CK-2127107 and started a Phase II clinical trial of CK-2127107 in patients with spinal muscular atrophy (SMA). CK-2127107 is also being evaluated for the use in other indications associated with muscle weakness.

Omecamtiv Mecarbil

The Company’s lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil, is a cardiac muscle myosin activator. COSMIC-HF is a Phase II, double-blind, randomized, placebo-controlled, multicenter, clinical trial designed to assess the pharmacokinetics and tolerability of omecamtiv mecarbil dosed orally in patients with heart failure and left ventricular systolic dysfunction, as well as its effects on echocardiographic measures of cardiac function. ATOMIC-AHF (Acute Treatment with Omecamtiv Me! carbil to Increase Contractility in Acute Heart Failure) is a double-blind, placebo-controlled, Phase IIb clinical trial of intravenous omecamtiv mecarbil in patients with left ventricular systolic dysfunction hospitalized with acutely decompensated heart failure.

The Company competes with Neuraltus Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Genervon Biopharmaceuticals, LLC, Orion Pharmaceuticals, Orphazyme, Mitsubishi Tanabe Pharma Corporation, Eisai Co., Ltd., MediciNova, Inc., BrainStorm Cell Therapeutics, Neuralstem, Inc., Roche, AveXis, Inc., Pfizer Inc., Bioblast Pharma, Ltd., Ligand Pharmaceuticals, Inc., GTx, Inc., Regeneron Pharmaceuticals, Inc., Eli Lilly & Company, Acceleron Pharma, Scholar Rock, Stealth Biotherapeutics, Novartis, ARCA biopharma, Inc., Bayer, Carpicor Therapeutics, Inc., Cardiorentis Ltd., Ono Pharmaceutical Company, Juventas Therapeutics, ARMGO Pharma, Inc, Trevena, Inc., Cardioxyl Pharmaceuticals, Inc., Zensun Sci & Tech, Ltd, Tenax Therapeutics, Isis Pharmaceuticals, Inc., Trophos SA, Acorda Therapeutics, Inc and Celladon Corporation.

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Cytokinetics Inc  (NASDAQ:CYTK)Q4 2018 Earnings Conference CallFeb. 21, 2019, 4:30 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Ethan Ryder]

    Cytokinetics (NASDAQ:CYTK) was upgraded by analysts at ValuEngine from a hold rating to a buy rating.

    Dean Foods (NYSE:DF) was upgraded by analysts at ValuEngine from a strong sell rating to a sell rating.

  • [By Ethan Ryder]

    Cytokinetics, Inc. (NASDAQ:CYTK) CEO Robert I. Blum sold 4,000 shares of the business’s stock in a transaction dated Friday, August 3rd. The stock was sold at an average price of $6.65, for a total transaction of $26,600.00. Following the sale, the chief executive officer now directly owns 168,022 shares of the company’s stock, valued at $1,117,346.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Top 5 Medical Stocks To Own Right Now: Allegheny Technologies Incorporated(ATI)

Allegheny Technologies Incorporated produces and sells specialty materials and components worldwide. The company operates through two segments, High Performance Materials and Components; and Flat-Rolled Products. The High Performance Materials and Components segment provides various high performance materials, including titanium and titanium-based alloys; nickel-and cobalt-based alloys and superalloys; zirconium and related alloys, such as hafnium and niobium, advanced powder alloys, and other specialty materials, in long product forms of ingots, billets, bars, rods, wires, shapes and rectangles, and seamless tubes, plus precision forgings, castings, components, and machined parts. This segment serves aerospace and defense, oil and gas, chemical process industry, electrical energy, and medical markets. The Flat-Rolled Products segment offers stainless steel, nickel-based alloys, specialty alloys, and titanium and titanium-based alloys in various product forms comprising plates, sheets, engineered strips, and precision rolled strip products, as well as grain-oriented electrical steel sheets. This segment serves oil and gas, chemical process industry, electrical energy, automotive, food processing equipment and appliances, construction and mining, electronics, communication equipment and computers, and aerospace and defense markets. The company sells its products through direct sales and independent representatives. Allegheny Technologies Incorporated was founded in 1960 and is headquartered in Pittsburgh, Pennsylvania.

Advisors’ Opinion:

  • [By Joseph Griffin]

    Shares of Allegheny Technologies Incorporated (NYSE:ATI) have received an average recommendation of “Buy” from the twelve analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $30.60.

  • [By Shane Hupp]

    Allegheny Technologies Incorporated (NYSE:ATI) VP Karl D. Schwartz sold 1,000 shares of Allegheny Technologies stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $26.79, for a total value of $26,790.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

  • [By Logan Wallace]

    Allegheny Technologies (NYSE:ATI) was downgraded by research analysts at ValuEngine from a “hold” rating to a “sell” rating in a report released on Tuesday.

Top 5 Medical Stocks To Own Right Now: Mitcham Industries Inc.(MIND)

Mitcham Industries, Inc., through its subsidiaries, engages in the leasing, sale, and service of geophysical and other equipment to the seismic industry worldwide. The company operates in two segments, Equipment Leasing and Seamap. The Equipment Leasing segment leases seismic equipment for short-term leasing primarily to seismic data acquisition contractors and oil field service providers. Its land equipment lease pool includes seismic recording land channels, geophones and cables, and other peripheral equipment; marine seismic equipment lease pool comprises streamers, air compressors, air guns, streamer positioning equipment, energy source controllers, and other equipment; and downhole equipment lease pool consist of downhole seismic tools. This segment is also involved in the sale of new seismic equipment of other manufacturers; heli-pickers and related equipment used in the deployment and retrieval of seismic equipment by helicopter; and equipment, consumables, systems integration, engineering hardware, and software maintenance support services to the seismic, hydrographic, oceanographic, environmental, and defense industries, as well as sells used equipment from its lease pool. The Seamap segment designs, manufactures, and sells a range of products for the marine seismic industry. Its products include GunLink seismic source acquisition and control systems, which are designed to provide operators of marine seismic surveys with precise control of energy sources; and BuoyLink RGPS tracking systems that are used to offer precise positioning of seismic sources and streamers. The company was founded in 1987 and is headquartered in Huntsville, Texas.

Advisors’ Opinion:

  • [By Stephan Byrd]

    First Wilshire Securities Management Inc. lowered its position in shares of Mitcham Industries, Inc. (NASDAQ:MIND) by 5.0% in the second quarter, according to the company in its most recent filing with the SEC. The firm owned 324,169 shares of the company’s stock after selling 17,005 shares during the quarter. First Wilshire Securities Management Inc. owned about 2.68% of Mitcham Industries worth $1,303,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Teton Advisors Inc. lifted its stake in Mitcham Industries, Inc. (NASDAQ:MIND) by 22.8% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 140,069 shares of the company’s stock after purchasing an additional 26,000 shares during the quarter. Teton Advisors Inc. owned about 1.16% of Mitcham Industries worth $563,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:

    Get Mitcham Industries alerts:

    Gaps Down – TRUE, MEIP, AMSC, CYTX, PRPH, MIND, CTG (fxpips.com) Mitcham Industries (MIND) Reports Q1 Loss of $0.52/Share (streetinsider.com) Edited Transcript of MIND earnings conference call or presentation 7-Jun-18 1:00pm GMT (finance.yahoo.com) Mitcham Industries down 4.5% post Q1 results (seekingalpha.com) Mitcham Industries, Inc. (MIND) Q1 2019 Results – Earnings Call Transcript (seekingalpha.com)

    Mitcham Industries traded up $0.04, hitting $4.16, during mid-day trading on Wednesday, Marketbeat.com reports. 27,560 shares of the company’s stock were exchanged, compared to its average volume of 27,820. Mitcham Industries has a fifty-two week low of $2.82 and a fifty-two week high of $4.57.

Top 5 Medical Stocks To Own Right Now: Salesforce.com Inc(CRM)

Salesforce is a leading provider of enterprise cloud computing solutions, with a focus on customer relationship management, or CRM. We introduced our first CRM solution in February 2000, and we have since expanded our service offerings with new editions, solutions, features and platform capabilities. Our mission is to help our customers transform themselves into customer-centric companies by empowering them to connect with their customers in entirely new ways. Our Customer Success Platform, including sales force automation, customer service and support, marketing automation, community management, analytics, application development, Internet of Things integration and our professional cloud services, provide the next-generation platform of enterprise applications, or apps, and services to enable customer success. Our service offerings are intuitive and easy-to-use, can be deployed rapidly, customized easily and integrated with other platforms and enterprise apps.   Advisors’ Opinion:

  • [By Daniel Sparks]

    Management also used the quarterly update to highlight DocuSign’s progress on improving its overall ecosystem with strong partner integrations, like its recent partnership with business-software company Salesforce (NYSE:CRM). DocuSign launched a solution on the Salesforce platform that helps businesses easily send documents for e-signatures, reduce administrative hassles like scanning and printing, and more. “Paired with Salesforce Essentials,” management explained in the earnings release, “the product helps small businesses accelerate the completion of agreements, ranging from quotes to contracts to sales orders and more.”

  • [By Motley Fool Staff]

    Enterprise software-as-a-service giant salesforce.com (NYSE:CRM) delivered a strong fourth-quarter earnings report, with revenue up by double-digit percentages, and it beat expectations on key metrics. Yet Wall Street bid its shares lower for the week.

Top 5 Medical Stocks To Own Right Now: Virtusa Corporation(VRTU)

Virtusa Corporation operates as an information technology (IT) services company. It offers business and IT consulting services comprising application inventory and portfolio assessment, business/technology alignment analysis, business process optimization, and quality assurance process consulting; accelerated solution design, enterprise architecture analysis, technology roadmaps, product evaluation and selection, and business process analysis and design; and program governance and change management, program management planning, and complex program management. The company also provides technology implementation services, such as application development, package implementation and integration, software product engineering, application maintenance and support, business process management, CRM and SAP implementation, customer experience and content management, enterprise mobility, cloud computing, and social media solutions; systems consolidation and rationalization, technology migration and porting, and legacy application Web-enablement; data management, business intelligence, reporting and decision support, master data management, data integration, and big data analytics; and software quality assurance and managed testing services. In addition, it offers application outsourcing services, such as the production support, application maintenance and enhancement, and ongoing software engineering; systems and database administration, and monitoring; outsourcing of quality assurance planning; and preparation and execution of test cases, scripts, and data. The company provides its services to communications and technology; banking, financial services, and insurance; and media and information industries worldwide. Virtusa Corporation has a strategic partnership with Hitachi, Ltd. The company was formerly known as eRunway, Inc. and changed its name to Virtusa Corporation in April 2002. Virtusa Corporation was founded in 1996 and is headquartered in Westborough, Massachusetts.

Advisors’ Opinion:

  • [By Motley Fool Transcribers]

    Virtusa Corp  (NASDAQ:VRTU)Q3 2019 Earnings Conference CallFeb. 07, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Ethan Ryder]

    Voya Investment Management LLC boosted its stake in Virtusa Co. (NASDAQ:VRTU) by 105.7% during the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 280,742 shares of the information technology services provider’s stock after acquiring an additional 144,258 shares during the period. Voya Investment Management LLC’s holdings in Virtusa were worth $13,666,000 as of its most recent SEC filing.